AIP
CCCC icon

Ameritas Investment Partners’s C4 Therapeutics CCCC Stock Holding History

Ameritas Investment Partners’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,744
Closed -$9.19K – 3222
2025
Q1 		$9.19K Hold
5,744
– – ﹤0.01% 2849
2024
Q4 		$20.7K Hold
5,744
– – ﹤0.01% 2620
2024
Q3 		$32.7K Hold
5,744
– – ﹤0.01% 2413
2024
Q2 		$26.5K Buy
+5,744
New +$34.3K ﹤0.01% 2491
2023
Q2 		– Sell
-2,962
Closed -$9.3K – 3128
2023
Q1 		$9.3K Hold
2,962
– – ﹤0.01% 2749
2022
Q4 		$24.4K Hold
2,962
– – ﹤0.01% 2480
2022
Q3 		$25K Hold
2,962
– – ﹤0.01% 2402
2022
Q2 		$22K Hold
2,962
– – ﹤0.01% 2503
2022
Q1 		$72K Hold
2,962
– – ﹤0.01% 1838
2021
Q4 		$95K Hold
2,962
– – ﹤0.01% 1709
2021
Q3 		$132K Buy
2,962
+262
+10% +$11.2K ﹤0.01% 1514
2021
Q2 		$102K Buy
2,700
+1,806
+202% +$64.7K ﹤0.01% 1708
2021
Q1 		$33K Hold
894
– – ﹤0.01% 2314
2020
Q4 		$30K Buy
+894
New +$25.9K ﹤0.01% 2272

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameritas Investment Partners's CCCC Position: Q2 2025 in Review

Ameritas Investment Partners sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 5,744 shares — an estimated $9.19K sold.

Ameritas Investment Partners first reported a position in CCCC in Q4 2020 and held it in 14 quarters. The position peaked at $132K in Q3 2021. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • Ameritas Investment Partners reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 5,744 C4 Therapeutics shares in Q2 2025, an estimated $9.19K.
  • Ameritas Investment Partners first reported a position in C4 Therapeutics in Q4 2020 and held it in 14 quarters.
  • Ameritas Investment Partners's C4 Therapeutics position peaked at $132K in Q3 2021.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.